Endocyte Reports Fourth Quarter and Year End 2016 Financial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
85
Endocyte Reports Fourth Quarter and Year End 2016 Financial Results and Provides Clinical and Pipeline Update

WEST LAFAYETTE, Ind., March 10, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ: ECYT ), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced financial results for the fourth quarter ending December 31, 2016, and provided a clinical and business update.

“We are pleased to report progress on several aspects of the business during the last several weeks,” commented Mike Sherman, president and CEO at Endocyte. “The separately announced collaboration with Seattle Children’s Research Institute and Dr. Michael Jensen, an innovator and thought leader in the field of chimeric antigen receptor T-cell (CAR T-cell) immunotherapies, is an indication of the promise of our technology and a reflection of our commitment to establishing partnerships intended to bring early stage programs to the clinic more rapidly and drive more value from our pipeline. Mike Andriole joining us as chief financial officer also adds significant experience and capacity to pursue value driving partnerships going forward.”

“We also anticipate receiving additional clinical data on our lead assets, EC1169 and EC1456, during 2017 as we advance two additional agents toward the clinic,” continued Mr. Sherman.

EC1169 (PSMA-tubulysin) Program Outline

  • Currently enrolling patients in the expansion phase of the EC1169 trial in up to 50 second-line chemotherapy and up to 50 taxane-naïve metastatic castrate-resistant prostate cancer (mCRPC) patients at a maximum clinical once per week dose of 6.5 mg/m 2
  • Patients are scanned with Endocyte’s proprietary imaging agent, EC0652, to identify the presence of disease that expresses prostate-specific membrane antigen (PSMA)
  • Primary endpoint of this expansion phase is radiographic progression-free survival (rPFS), measured at 5 months for taxane-naïve mCRPC patients and at 3 months for second-line chemotherapy patients
  • Secondary endpoints which will provide earlier insight into drug activity include overall response rates as measured by response evaluation criteria in solid tumors (RECIST) 1.1 and prostate-specific antigen (PSA)
  • Enrollment is not limited based on the results of the scan with EC0652 but primary endpoints of the trial are to be assessed in PSMA-positive patients

EC1456 (Folate-tubulysin) Program Outline

  • Currently enrolling expansion cohort of up to 40 folate-receptor (FR) positive non-small cell lung cancer (NSCLC) patients, as determined by an etarfolatide scan, to receive the maximum clinical twice per week dose of 6.0 mg/m 2  
  • Patients included in this expansion phase of the trial will have received first-line chemotherapy and may have also been treated with anti-PD-1 therapy
  • Exploring a more frequent dosing schedule, four times per week, in indications that are typically FR-positive, such as ovarian and endometrial cancers
  • Also conducting an ovarian cancer surgical study to assess various attributes of the drug release within targeted tumors

Upcoming Expected Milestones

  • Safety and efficacy updates for both EC1169 and EC1456 ongoing clinical trials expected at the Annual Meeting of the American Society of Clinical Oncology in June, 2017
  • Updated pre-clinical data for CAR T-cell program expected to be presented at a medical conference in the first half of 2017
  • Expect to file Investigational New Drug (IND) application for EC2629 in mid 2017.  EC2629 leverages a proprietary warhead with a dual mechanism of action: targeting both FR+ cancer cells and tumor associated macrophages (TAMs)
  • Completion of pre-clinical evaluations for CAR T-cell program expected in second half of 2017
  • Initiation of enrollment for EC2629 phase 1 trial expected in second half of 2017
  • Pre-clinical preparatory work on EC2319 in anticipation of potential IND in 2018. EC2319 targets and disables activated macrophages which otherwise produce pro-inflammatory cytokines associated with chronic inflammatory disease

Fourth Quarter 2016 Financial Results

Endocyte reported a net loss of $11.1 million, or $0.26 per basic and diluted share, for the fourth quarter of 2016, compared to a net loss of $9.8 million, or $0.23 per basic and diluted share for the same period in 2015.

Research and development expenses were $8.2 million for the fourth quarter of 2016, compared to $6.4 million for the same period in 2015. The increase was primarily attributable to increases in expenses related to the EC1169 phase 1 trial, including drug manufacturing expenses.

General and administrative expenses were $3.1 million for the fourth quarter of 2016, compared to $3.5 million for the same period in 2015. The decrease was primarily attributable to a decrease in compensation expense, which was partially offset by an increase in expenses related to patent and recruiting fees. 

Cash, cash equivalents and investments were $138.2 million at December 31, 2016, compared to $146.7 million at September 30, 2016, and $173.6 million at December 31, 2015.

Financial Expectations

The company anticipates its cash balance at the end of 2017 to be approximately $100 million.

About EC1456 and etarfolatide

EC1456 is an investigational therapeutic SMDC constructed of a high affinity FR-targeting ligand conjugated through a spacer and bioreleasable linker system to a potent cytotoxic microtubule inhibitor, TubBH. Patient FR-status is determined using the investigational companion imaging agent, etarfolatide.

About EC1169 and EC0652

EC1169 is an investigational therapeutic SMDC constructed of a high affinity prostate specific membrane antigen (PSMA)-targeting ligand conjugated through a bioreleasable linker system to a potent microtubule inhibitor, tubulysin B hydrazide (TubBH). Patient PSMA-status is determined using the investigational companion imaging agent, EC0652.

Conference Call

Endocyte management will host a conference call today at 8:30 a.m. EST.

U.S. and Canadian participants:      (877) 845-0711
International:      (760) 298-5081                    

A live, listen-only webcast of the conference call may also be accessed by visiting the Investors & News section of the Endocyte website, www.endocyte.com .

The webcast will be recorded and available on the company's website for 90 days following the call.

Website Information Endocyte routinely posts important information for investors on its website,  www.endocyte.com , in the “Investors & News” section.  Endocyte uses this website as a means of disclosing material information in compliance with its disclosure obligations under Regulation FD.  Accordingly, investors should monitor the “Investors & News” section of Endocyte’s website, in addition to following its press releases, SEC filings, public conference calls, presentations and webcasts.  The information contained on, or that may be accessed through, Endocyte’s website is not incorporated by reference into, and is not a part of, this document.

About Endocyte

Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer and other serious diseases.  Endocyte uses its proprietary drug conjugation technology to create novel SMDCs and companion imaging agents for personalized targeted therapies.  The company’s SMDCs actively target receptors that are over-expressed on diseased cells relative to healthy cells.  This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently and over longer periods of time than would be possible with the untargeted drug alone.  The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. For additional information, please visit Endocyte’s website at www.endocyte.com .

Forward Looking Statements

Certain of the statements made in this press release are forward looking, such as those, among others, relating to future spending, future cash balances, the successful completion of current and future clinical trials, the enrollment period for, and availability and reporting, of data from ongoing and future clinical trials, and the company's future development plans including those relating to the completion of pre-clinical development in preparation for possible future clinical trials. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include risks that the company may experience delays in the completion of its clinical trials (whether caused by competition, adverse events, patient enrollment rates, shortage of clinical trial materials, regulatory issues or other factors); risks that data from its clinical trials may not be indicative of subsequent clinical trial results; risks related to the safety and efficacy of the company’s product candidates; risks that early stage pre-clinical data may not be indicative of subsequent data when expanded to additional pre-clinical models or to subsequent clinical data; risks that evolving competitive activity and intellectual property landscape may impair the company's ability to capture value for the technology; risks that expectations and estimates turn out to be incorrect, including estimates of the potential markets for the company’s product candidates, estimates of the capacity of manufacturing and other facilities required to support its product candidates, projected cash needs, and expected future revenues, operations, expenditures and cash position. More information about the risks and uncertainties faced by Endocyte, Inc. is contained in the company’s periodic reports filed with the Securities and Exchange Commission. Endocyte, Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Endocyte, Inc.  
Statements of Operations  
(dollars in thousands, except per share amounts)  
(unaudited)  
   
    For the Three Months Ended December 31,     For the Twelve Months Ended December 31,  
    2015       2016       2015       2016  
                         
Collaboration revenue   $ 12       $ 12       $ 70       $ 70  
Costs and expenses:                                
Research and development     6,386         8,188         26,309         27,492  
General and administrative     3,527         3,096         15,734         17,298  
Total costs and expenses     9,913         11,284         42,043         44,790  
Loss from operations     (9,901 )       (11,272 )       (41,973 )       (44,720 )
                                 
Interest income, net     162         232         652         861  
Other income (expense), net     (55 )       (25 )       51         (29 )
Net loss   $ (9,794 )     $ (11,065 )     $ (41,270 )     $ (43,888 )
                                       
Net loss per share - basic and diluted   $ (0.23 )     $ (0.26 )     $ (0.98 )     $ (1.04 )
                                       
Comprehensive loss   $ (9,897 )     $ (11,137 )     $ (41,205 )     $ (43,849 )
                                       
Weighted average number of common shares used in net loss – basic and diluted per share:     41,984,763         42,289,453         41,939,504         42,210,643  
Endocyte, Inc.  
Balance Sheets  
(in thousands)  
   
    As of December 31,     As of December 31,  
    2015     2016  
          (unaudited)  
Assets                
Cash, cash equivalents and investments   $ 173,600     $ 138,207  
Other assets     4,786       5,287  
Total assets   $ 178,386     $ 143,494  
                 
Liabilities and stockholders’ equity                
Current liabilities   $ 6,189     $ 5,562  
Deferred revenue and other liabilities, net of current portion     851       785  
Total stockholders’ equity     171,346       137,147  
Total liabilities and stockholders’ equity   $ 178,386     $ 143,494  

Contact: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, stephanie@sternir.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Duolingo Faces Class Action: Key Investor Steps

Updated Category News Views 75

Navigating Turbulent Times with Duolingo Holy moly, the dumpster fire that is the Duolingo (NASDAQ:DUOL) legal saga just got hotter. If you snagged yourself some shares between May 2, 2025, and February 26, 2026, you'd better sit down and grab some antacids—because the nauseating roller coaster is far from over. Robbins LLP is rounding up the troops for a class action,...

Continue Reading
Scientific Games Joins NCPG’s 2026 Campaign Again

Updated Category News Views 142

Scientific Games Backs Responsible Gaming Again It's another year, and here's Scientific Games once more, guns blazing for a cause that's needed more than a few times over—responsible gambling. Those folks got their hearts in the right place, joining the National Council on Problem Gambling's 2026 Gift Responsibly campaign. Ninth time running, no less! It's like...

Continue Reading
Dr. Kumar Joins Florida Cancer Specialists Team

Updated Category News Views 141

Welcoming a New Oncology Specialist to Bradenton What does a small but mighty addition mean for cancer care in Bradenton, Florida? Well, it feels like a big win for the locals. Dr. Vinod Kumar is the latest name to join the ranks of the Florida Cancer Specialists & Research Institute (FCS) at the Bradenton Cancer Center. With years under his belt in medical oncology and...

Continue Reading
SANY's Bold AI Showdown at bauma CHINA 2026

Updated Category News Views 27

SANY's Future Vision: AI Agents and Robotic Machinery The construction machinery game is about to get a whole lot smarter, if SANY has anything to say about it. They're rolling out their biggest show ever at bauma CHINA 2026, and the headline act? A fresh breed of AI agents and robotic machinery that promises to revolutionize the industry. Marking its 40-year legacy, SANY...

Continue Reading
Saint Luis Rey Launches Exclusive Palatinos Vitola

Updated Category News Views 89

New Beginnings for the Saint Luis Rey Brand You think you've seen it all in the cigar world, but then comes a debut like this that lights a fire under the lush tradition of Cuba. Enter Saint Luis Rey's new Palatinos vitola, a blend wrapped in the mystique of exclusivity for La Casa del Habano and Habanos Specialists. Whether you're a seasoned connoisseur or just dipping...

Continue Reading
iHeartMedia Faces 65% Drop: Fraud Investigation Launched

Updated Category News Views 62

Trouble Tunes for iHeartMedia Investors Alright folks, here's the skinny on iHeartMedia, Inc. These days, it's like everyone's out for a piece of iHeart, and not in the way you'd wanna see—unless you're SBS Law, those shareholder rights hotshots diving into another pond of legal ripples. Seems a heap of head-scratching's going down on their version of transparency with...

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 301

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
Cheyenne Real Estate: Neighborhood Nuances and Choices

Updated Category News Views 128

Unearthing the Hidden Dynamics of Cheyenne's Real Estate You've got this picturesque vision in your head of Cheyenne, Wyoming—a sprawling cowboy town with its wild winds and wide-open spaces. But if you think all those neighborhoods are cut from the same cloth, you've got another thing coming. The real estate scene here is just as varied as the prairies stretching out...

Continue Reading
TCL Unveils Black Friday Steals on Smart Devices

Updated Category News Views 104

TCL's Big Move This Holiday Season When was the last time you saw a deal that actually made you stop and check your wallet? Well, TCL is giving you a reason to dig deep this Black Friday and Cyber Monday. They're slashing prices across smartphones and tablets, trying to elbow their way into your shopping cart with discounts up to $150. Now that's the kind of aggressive...

Continue Reading
Elite Robots Expands Global Reach with Mobile Manipulators

Updated Category News Views 112

Robots Hitting the Road? Picture this: robots that aren't just bolted to a factory floor but roam the production lines like tireless workers on wheels. That's what Elite Robots is betting on with their shiny new ELITEMISSION mobile manipulators. Not Just Any Old Robot These bad boys combine a robotic arm with an autonomous mobile platform. Think of an octopus getting off...

Continue Reading
d -->

Top 5 Most Recently Viewed Articles

Market Fluctuations: NVIDIA, Micron, and SMCI Stocks Overview

Updated Category News Views 192

Market Update for NVIDIA, Micron, and SMCI Stocks Shares of NVIDIA Corp. (NASDAQ: NVDA), Super Micro Computer, Inc. (NASDAQ: SMCI), and Micron Technology, Inc. (NASDAQ: MU) have recently taken a noticeable dip. This drop has caught the eye of both investors and market analysts, leading to questions about what might be driving this trend. Current Hurdles in the...

Continue Reading
Hyundai Motor Shines at Cannes with Grand Prix and Gold Lions

Updated Category News Views 250

Hyundai Motor's Exceptional Recognition at Cannes Lions Hyundai Motor Company has made a remarkable impact at the prestigious Cannes Lions International Festival of Creativity. The company has achieved a Grand Prix award for its short film, 'Night Fishing,' a project that has been praised for its inventive storytelling and creative prowess. This Grand Prix marks a...

Continue Reading
EWTN's Expansion in Stockholm: A Strategic Faith Move

Updated Category News Views 54

A Bold Move into Northern Europe In what's shaping up to be a calculated leap of faith, the EWTN Global Catholic Network opened a new office in Stockholm, Sweden. Now, I don't usually get all warm and fuzzy over religious broadcasts, but this is less about spreading sermons and more about tapping into a growing market. Yeah, you heard me right—market. With the Catholic...

Continue Reading
Investors Urged to Act Now Amid 143% Cash Flow Decline

Updated Category News Views 135

Significant Concerns for StubHub Investors Investors in StubHub Holdings, Inc. (NYSE: STUB) are being urged to pay close attention as serious allegations surface concerning the company's recent financial disclosures. The prominent investor rights law firm Hagens Berman is reaching out to those investors who acquired shares during the company's Initial Public Offering...

Continue Reading
Walmart Leverages Automation to Rival Amazon's Dominance

Updated Category News Views 200

Walmart Ignites Technological Transformation Walmart Inc (NYSE: WMT) is not just a retailer; it's transforming into a technology powerhouse. While many might think of Amazon.com Inc (NASDAQ: AMZN) as the leader in tech-driven logistics, Walmart is ramping up its efforts. Recently, during a call with investors, the company's CFO highlighted a key milestone: "More than 50%...

Continue Reading